Recent Drug Developments and Law Update

Recent Drug Developments and Law Update 2022 is Sunday, March 6th Hosted remotely via Zoom

PLEASE NOTE: Due to the pandemic there are no group site locations to attend. This program is being offered as individual continuing education on a personal computer or mobile device.

REGISTRATION WILL CLOSE Friday, March 4th at 5:00 pm
CANCELLATION POLICY: No refunds after Tuesday, March 1st


Presentations - Sunday March 6th, 2022

“Law and MPDR Updates 2022”
“New Pharmacologic Tools for Symptomatic Management of Parkinson’s Disease Since 2018”
“COVID-19 Treatment With Focus on Antivirals”
“Updates to the 2021 Rheumatoid Arthritis Guidelines and New Medications for Rheumatic Diseases”
“Challenge Accepted? A Review of Child-Specific Psychiatric Conditions and Their Treatment”


New drugs and new guideline recommendations continue to affect medical practice.  This program will discuss new therapies for Parkinson’s disease.  Recent updates for the treatment of psychiatric conditions in children will be presented.  Treatment of COVID-19 will be covered.  Treatment of rheumatic diseases will be discussed.  An update from the Montana Board of Pharmacy and information on the Montana Prescription Drug Registry will also be included


The goal of this program is to discuss new drugs, to compare them to other agents in the same pharmacological and/or therapeutic class, and to discuss where these new agents fit into disease state management.  In addition, an update of federal and Montana state pharmacy laws will be provided.


At the conclusion of this program, the participant should be able to:

  • List legislative and regulatory updates impacting the practice of pharmacy in Montana
  • Describe new functionality within the Montana Prescription Drug Registry
  • Compare and contrast medications for Parkinson’s disease approved since 2018
  • List new agents in the pipeline (phase 3 studies) for symptomatic management of Parkinson’s disease
  • Given a patient case or scenario, select the most appropriate medication for symptomatic management of Parkinson’s disease
  • Compare and contrast mechanism of action and efficacy to treat COVID-19 infection between three antivirals: remdesivir, molnupiravir and paxlovid
  • Given a patient scenario, be able to recommend the best therapy options based on NIH COVID-19 treatment guidelines
  • Compare new monoclonal antibodies for systemic lupus erythematosus and lupus nephritis
  • Discuss the role of oral JAK inhibitors in rheumatic disease
  • Differentiate between common child-specific psychiatric conditions
  • Summarize current pharmacologic treatment options for neurodevelopmental, disruptive, impulse-control, and conduct disorders

Activity Type: Knowledge-based

Target Audience: Pharmacists & Pharmacy Technicians (law portion only)

Accreditation Information

Skaggs School of Pharmacy at The University of Montana is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based activity. The Universal Activity Number (UAN) for the Recent Drug Development portion is #0035-0000-22-015-L01-P, and approved for 5 hours or .50 CEUs.  The Universal Activity Number for the Recent Law portion is #0035-0000-22-016-L03-P/T, and approved for 1 hour or .10 CEUs.  In order to receive credits, participants must sign in to the presentation, must view the entire presentation, and complete the program evaluation. CE credits will be uploaded to CPE Monitor within 60-days after the program.


Disclosure of Potential Conflicts of Interest: Skaggs School of Pharmacy at The University of Montana did not receive payment or services from a third party for any aspect of this activity and has no relationships (financial or other) with entities or activities that could be perceived to influence, or that give the appearance of potentially influencing any portion of this activity.

Program Coordinator

Sherrill Brown, DVM, Pharm. D., BCPS
Director, Drug Information Service
The University of Montana, College of Health


Marcie Bough, Pharm.D., Executive Officer, Montana Board of Pharmacy

Andrew Glueckert, PharmD, St. Peter’s Hospital

Nikki Griffis, PharmD, Montana Board of Pharmacy

Joshua Loveland, PharmD, Shodair Children’s Hospital

Rose Macklin, PharmD, BCPS, Partners in Home Care

Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, University of Montana Skaggs School of Pharmacy

Megan Murphy, PharmD, BCPS, CCP, St. Peter’s Hospital